TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence

Gongwei Wu(Harvard University), Myles Brown(Harvard University), Noriaki Yoshida(Dana-Farber Cancer Institute), Eric S. Fischer(Dana-Farber Cancer Institute), Lu Yang(City Of Hope National Medical Center), Katherine A. Donovan(Harvard University), M. Jones(Harvard University), Wing C. Chan(Ontario Institute for Cancer Research), Jihe Liu(Harvard University), Hojong Yoon(Harvard University), David M. Weinstock(Broad Institute), Tiffany Chang(Memorial Sloan Kettering Cancer Center), Abner Louissaint(Massachusetts General Hospital), Renee Chen(National Institutes of Health), Yanming Zhang(Memorial Sloan Kettering Cancer Center), Tayla B. Heavican‐Foral(Dana-Farber Cancer Institute), Geoffrey M. Nelson(MRC Laboratory of Molecular Biology), Wenchao Wu(State Key Laboratory of Oncology in South China), Kristen L. Jones(Oregon Health & Science University), Natasha Galasso(Memorial Sloan Kettering Cancer Center), Chun‐Wei Chen(Chang Gung University), Paola Dal Cin(Brigham and Women's Hospital), Steven M. Horwitz(Memorial Sloan Kettering Cancer Center), Lydie Debaize(Harvard University), Elisa Mandato(University of Padua), Karen Adelman(National Institutes of Health), Mikhail Roshal(Memorial Sloan Kettering Cancer Center), Ajit J. Nirmal(Brigham and Women's Hospital), Salvia Jain(Broad Institute), Andrew L. Feldman(Mayo Clinic in Arizona), Xiaoyang Zhang(University of Utah), Ran Xu(Harvard University), Kristen E. Stevenson(Dana-Farber Cancer Institute), Nivetha Ganesan(Memorial Sloan Kettering Cancer Center), Huiyun Liu(Dana-Farber Cancer Institute), Samuel Y. Ng(National Cancer Institute), Catharine Leahy(Harvard University), Shannan J. Ho Sui(Harvard University), Yuan Xiong(Harvard University)
Science Translational Medicine
September 20, 2023
Cited by 13


Related Papers